Treatment of depression with associated anxiety: Comparison of tricyclic antidepressant and selective serotonin reuptake inhibitors

Acta Psychiatrica Scandinavica, Supplement

Volumn 101, Issue 403, 2000, Pages 9-16

  Montgomery, S A ^a   Judge, R ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Antidepressant; Anxiety; Depression; SSRI; TCA

Indexed keywords

CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY; ANXIETY NEUROSIS; ASTHENIA; COMORBIDITY; CONFERENCE PAPER; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INSOMNIA; PATIENT COMPLIANCE; RISK BENEFIT ANALYSIS; SOMNOLENCE; THOUGHT DISORDER; ANXIETY DISORDER; ARTICLE; COMPARATIVE STUDY; MAJOR DEPRESSION;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY DISORDERS; CLOMIPRAMINE; DEPRESSIVE DISORDER, MAJOR; FLUOXETINE; HUMANS; IMIPRAMINE; SEROTONIN UPTAKE INHIBITORS;

EID: 0034564194     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. The detection and consequences of anxiety in clinical depression
2. Anxious and nonanxious depression
3. Anxiety symptom relief in depression treatment outcomes
4. Depression with anxiety and atypical depression
5. Feeling hopeless and helpless: When anxiety symptoms coexist with depressive disorder
6. Management of patients with depression associated with anxiety symptoms
7. Anxiety disorders in primary care: A life-span perspective
8. Treating comorbid depression and anxiety
9. Targeting treatment in patients with mixed symptoms of anxiety and depression
10. Anxiolytic antidepressant augmentation
11. Diagnostic dilemmas presented by patients with anxiety and depression
12. The behavioural toxicity of antidepressants: Effects on cognition and sexual function
13. Evolutionary trends in the pharmacotherapeutic management of depression
14. Fluoxetine versus tricyclic antidepressants: A prospective multicenter study of antidepressant drug overdoses
15. Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: A comparative trial of fluoxetine versus imipramine
16. Fluoxetine versus clomipramine in major depressive disorders
17. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety
18. A double-blind comparison of sertraline and clomipramine in the treatment of major depressive disorder and associated anxiety in general practice
19. Antidepressant efficacy in relation to item analysis and severity of depression: A placebo-controlled trial of fluvoxamine versus imipramine
20. Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features
21. Course of psychomotor agitation during pharmacotherapy of depression: Analysis from double-blind controlled trials with fluoxetine
22. SSRIs in anxious-agitated depression: A post-hoc analysis of 279 patients
23. The anti-anxiety and anti-agitation effects of paroxetine in depressed patients
24. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression
25. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression
26. A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression
27. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients
28. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression
29. A double blind comparison of paroxetine and fluoxetine in patients with major depression
30. A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression
31. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression
32. Fluoxetine versus sertraline and paroxetine in major depression: Efficacy and tolerability in patients with high or low baseline anxiety